We anticipate Amgen to serve Roche an official court summons towards 3/06 timeframe upon which Roche will respond and the patent litigation suit will be in process. Ultimately, we continue to believe that Amgen will successfully defend its erythropoietin patents and that CERA will be found to have infringed.
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking "Got It!," you consent to our use of cookies.